0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effect of the Diabetic Nephropathy Aggravation Prevention Program on medical visit behavior in individuals under the municipal national health insurance

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Aims/Introduction

          We aimed to clarify the effectiveness of the Diabetic Nephropathy Aggravation Prevention Program in Japan by comparing the diabetes‐related medical visit behavior of individuals under the municipal national health insurance according to insurers' effort levels.

          Materials and Methods

          We assessed changes in medical visit behavior according to insurers' effort levels, “Full Efforts,” “Some Efforts” and “No Effort,” using longitudinal data from the National Database of Health Insurance Claims and Specific Health Checkups before 2015 and after 2018 regarding the national health insurance programs in Japan. We analyzed the effect of the Diabetic Nephropathy Aggravation Prevention Program using a generalized linear mixed model for 208,388 participants with diabetes.

          Results

          The additive effect on medical visit behavior was significantly higher for insurers with “Full Efforts” than for those with “No Effort;” the coefficient (log odds ratio) was 0.159 (95% confidence interval 0.063–0.256). The additive effects on medical visit behavior sizes for the people with hemoglobin A1c ≥7.0%, positive urinary protein and systolic blood pressure ≥140 mmHg were 0.508, 0.402 and 0.232, respectively, which were larger than the overall effect size (0.159) for insurers with “Full Efforts.”

          Conclusions

          Our findings showed that insurer efforts had an additive effect on the increase in the number of medical visits, suggesting that this national program could reduce the number of end‐stage renal failures or dialysis in Japan.

          Abstract

          We present novel findings on the effects of insurer efforts on medical visit behavior in the Diabetic Nephropathy Aggravation Prevention Program; we showed that insurer efforts actively encouraged patients to undergo medical visits.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          Diabetes self-management education for adults with type 2 diabetes mellitus: A systematic review of the effect on glycemic control.

          Assess effect of diabetes self-management education and support methods, providers, duration, and contact time on glycemic control in adults with type 2 diabetes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013).

            A nationwide survey of 4325 dialysis facilities was conducted at the end of 2013, among which 4268 (98.7%) responded. The number of new dialysis patients was 38,095 in 2013. Since 2008, the number of new dialysis patients has remained almost the same without any marked increase or decrease. The number of dialysis patients who died in 2013 was 30,751. The dialysis patient population has been growing every year in Japan; it was 314,438 at the end of 2013. The number of dialysis patients per million at the end of 2013 was 2470. The crude death rate of dialysis patients in 2013 was 9.8%. The mean age of new dialysis patients was 68.7 years and the mean age of the entire dialysis patient population was 67.2 years. The most common primary cause of renal failure among new dialysis patients was diabetic nephropathy (43.8%). The actual number of new dialysis patients with diabetic nephropathy has almost been unchanged for the last few years. Diabetic nephropathy was also the most common primary disease among the entire dialysis patient population (37.6%), followed by chronic glomerulonephritis (32.4%). The percentage of dialysis patients with diabetic nephropathy has been increasing continuously, whereas the percentage of dialysis patients with chronic glomerulonephritis has been decreasing. The number of patients who underwent hemodiafiltration (HDF) at the end of 2013 was 31,371, a marked increase from that in 2012. This number is more than twice that at the end of 2011 and approximately 1.5 times the number at the end of 2012. In particular, the number of patients who underwent online HDF increased approximately fivefold over the last 2 years. Among 151,426 dialysis patients with primary causes of renal failure other than diabetic nephropathy, 10.8% had a history of diabetes. Among those with a history of diabetes, 26.8% used glycoalbumin as an indicator of blood glucose level; and 33.0 and 27.6% were administered insulin and dipeptidyl peptidase (DPP)-4 inhibitor, respectively, as a medication of diabetes. The facility survey showed that 9392 patients underwent peritoneal dialysis (PD). The patient survey revealed that 1920 of these PD patients also underwent another dialysis method using extracorporeal circulation, such as hemodialysis (HD) or HDF. The number of patients who underwent HD at home at the end of 2013 was 461, a marked increase from that at the end of 2012 (393).
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              [Definition and the diagnostic standard for metabolic syndrome--Committee to Evaluate Diagnostic Standards for Metabolic Syndrome].

                Bookmark

                Author and article information

                Contributors
                kabayama@sahs.med.osaka-u.ac.jp
                Journal
                J Diabetes Investig
                J Diabetes Investig
                10.1111/(ISSN)2040-1124
                JDI
                Journal of Diabetes Investigation
                John Wiley and Sons Inc. (Hoboken )
                2040-1116
                2040-1124
                24 March 2023
                June 2023
                : 14
                : 6 ( doiID: 10.1111/jdi.v14.6 )
                : 782-791
                Affiliations
                [ 1 ] Division of Health Sciences Osaka University Graduate School of Medicine Suita Osaka Japan
                [ 2 ] Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology Gifu University Graduate School of Medicine Gifu Gifu Japan
                [ 3 ] Graduate Schools of Nutrition Sciences Kagawa Nutrition University Sakado Saitama Japan
                [ 4 ] Department of Nephrology and Hypertension, Kawasaki Medical School Kurashiki Okayama Japan
                Author notes
                [*] [* ] Correspondence

                Mai Kabayama

                Tel.: +81‐6‐6879‐2522

                Fax: +81‐6‐6879‐2522

                E‐mail address: kabayama@ 123456sahs.med.osaka-u.ac.jp

                Author information
                https://orcid.org/0000-0002-1238-449X
                https://orcid.org/0000-0003-4436-7456
                Article
                JDI14006 JDI-OA-2022-0580.R1
                10.1111/jdi.14006
                10204177
                36960735
                4042ed49-353b-4616-a73f-820a056843d8
                © 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 01 February 2023
                : 31 October 2022
                : 27 February 2023
                Page count
                Figures: 3, Tables: 5, Pages: 791, Words: 6761
                Funding
                Funded by: the Ministry of Health, Labor, and Welfare to verify the effectiveness of the “Diabetic Nephropathy Aggravation Prevention Program”
                Categories
                Original Article
                Articles
                Clinical Science and Care
                Custom metadata
                2.0
                June 2023
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.8 mode:remove_FC converted:23.05.2023

                health insurance claims,medical visit behavior,national database

                Comments

                Comment on this article